QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Ardent Health Inc. (ARDT)

Healthcare

Actionable
Fundamental
3
Sentiment
3
Technical
4

Buy pullback (pullback_to_support): limit 17.55 at the three-session 17.51-17.55 support shelf within a confirmed post-earnings uptrend (ADX 48.5 rising, MACD 1.68 above signal); stop 16.74 (Change-A 1.0xATR floor), T1 19.17 (+2.0xATR), T2 20.39 (+3.5xATR), R/R 2.00. Breakout-stop alternative above the settled 18.57 swing high was evaluated and rejected at R/R 1.30 (< 1.5).

Analysis as of 2026-11-12· more than 2 trading days ago

Company overview

Ardent Health, Inc. operates a network of hospitals and clinics in the United States, providing a range of healthcare services including general and specialty care. The company offers inpatient and ambulatory care, telehealth services, and operates acute care hospitals. It is a subsidiary of EGI-AM Investments, L.L.C.

Fundamental

fair
Fundamental3
Mixed fundamentals

Ardent Health shows cash generation but faces litigation and reimbursement risks, resulting in a mixed fundamental outlook.

Mixed fundamentals: a cash-generative hospital operator with about $6.45B of trailing revenue, an 11.3% trailing free-cash-flow yield, 3.1x lease-inclusive net leverage and 6.4x interest coverage, whose thin 2.3% net margin, active securities class action over receivables and insurance-reserve accounting, and roughly $708M of Medicaid supplemental revenue facing 2026 program cuts offset an improving 2026 earnings trajectory and a raised Adjusted EBITDA outlook.

Sentiment

fair
Sentiment3
Constructive sentiment

Sentiment is stable with no immediate catalysts, and media coverage is flat.

Q3 2026 results (announced, 2026-11-04) are the dominant catalyst: EPS of $0.31 against a $0.24 consensus plus a raised FY2026 adjusted EBITDA guidance midpoint were scored net-positive by the in-window tape (Zacks beat note +0.60, Benzinga earnings-call transcript +0.55), but the print is eight days old and the shares have already re-rated above every published target in the coverage set, leaving it only partially priced. Media sentiment is flat versus baseline (+0.084 over 2026-08-14 to 2026-10-13 versus +0.128 over 2026-10-29 to 2026-11-12), the retail leg is unmeasurable because Reddit access was blocked, and the Red-Flag Screen is clean with no severe or moderate flag fired and no cap applied.

Technical

good
Technical4
Confirmed uptrend

The stock is in a confirmed uptrend with strong trend strength and momentum indicators.

Post-earnings momentum continuation on a controlled three-session pullback. ARDT trades above every key average except TEMA14 18.28 — SMA20 13.70, SMA50 12.00, SMA200 10.31, EMA9 16.20, EMA21 14.33, WMA9 16.91, WMA21 14.72, DEMA14 17.31 — with ADX14 48.48 and rising from 46.35, so trend strength is high and directionally aligned with the upside. MACD is positive and above signal (1.68/1.10, histogram +0.58) although the histogram is contracting from 0.66, and RSI14 has cooled from 86.60 to 78.76. The 2026-11-04 to 2026-11-06 breakout (11.71 to 17.30 on 3.47M shares) is being digested above the 17.51 shelf with session lows of 17.51 / 17.77 / 17.55 and declining volume (3.47M, 1.59M, 0.75M, 0.61M, 0.32M), i.e. no distribution. Score 4: trend and trend strength are decisively bullish; the one weak signal is short-term extension (overbought RSI/Williams, 2026-11-12 close at the session low, price below TEMA14 and today's VWAP 17.82), which the 1.0xATR stop is sized to absorb.

You’re looking at 2026-11-12 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.